Skip to main content

Table 1 Baseline demographics and clinical characteristics of trial participants

From: Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD

  All patients Night-time awakening at baseline No night-time awakening at baseline
Tiotropium Placebo Tiotropium Placebo Tiotropium Placebo
(n = 544) (n = 357) (n = 280) (n = 179) (n = 264) (n = 178)
Age, years 65.11 ± 8.50 65.30 ± 8.84 63.86 ± 8.68 63.56 ± 8.86 66.44 ± 8.12 67.05 ± 8.50
Male, n (%) 363 (66.7) 227 (63.6) 186 (66.4) 115 (64.2) 177 (67.0) 112 (62.9)
Race, n (%)
 White 518 (95.2) 330 (92.4) 263 (93.9) 159 (88.8) 255 (96.6) 171 (96.1)
 Black 26 (4.8) 25 (7.0) 17 (6.1) 19 (10.6) 9 (3.4) 6 (3.4)
 Asian 0 (0.0) 2 (0.6) 0 (0.0) 1 (0.6) 0 (0.0) 1 (0.6)
Body mass index, kg/m2 28.32 ± 5.66 28.07 ± 5.96 28.32 ± 5.58 27.59 ± 6.00 28.32 ± 5.77 28.55 ± 5.89
Alcohol use, n (%)
 Non-drinker 284 (52.2) 174 (48.7) 152 (54.3) 89 (49.7) 132 (50.0) 85 (47.8)
 Average consumption 259 (47.6) 181 (50.7) 128 (45.7) 89 (49.7) 131 (49.6) 92 (51.7)
 Excessive consumption 1 (0.2) 2 (0.6) 0 (0.0) 1 (0.6) 1 (0.4) 1 (0.6)
Smoking history, pack-years 62.59 ± 30.68 59.21 ± 30.53 64.31 ± 32.31 59.25 ± 31.41 60.77 ± 28.80 59.17 ± 29.72
Duration of COPD, years 8.64 ± 7.42 8.05 ± 6.70 8.88 ± 7.56 8.64 ± 7.42 8.38 ± 7.28 7.47 ± 5.84
Rescue medication use/24 h 3.66 ± 2.71 3.44 ± 2.57 4.30 ± 2.92 4.08 ± 2.77 2.99 ± 2.28 2.80 ± 2.18
FEV1, L 1.05 ± 0.41 1.01 ± 0.44 1.05 ± 0.42 1.00 ± 0.42 1.05 ± 0.41 1.02 ± 0.46
FEV1, % predicted (Morris equation [11]) 38.02 ± 14.07 37.44 ± 14.18 36.88 ± 13.75 36.36 ± 13.91 39.22 ± 14.32 38.53 ± 14.41
FEV1, % predicted (ECSC equation [13]) 36.29 ± 13.48 35.74 ± 13.62 35.22 ± 13.20 34.75 ± 13.38 37.43 ± 13.71 36.75 ± 13.82
FVC, L 2.31 ± 0.79 2.23 ± 0.78 2.28 ± 0.79 2.22 ± 0.78 2.35 ± 0.79 2.25 ± 0.78
FEV1/FVC, % 45.96 ± 11.60 45.51 ± 11.70 46.59 ± 11.52 45.52 ± 11.93 45.30 ± 11.67 45.51 ± 11.49
  1. Data are mean ± standard deviation or number of patients (%)
  2. COPD, chronic obstructive pulmonary disease; ECSC, European Community for Steel and Coal; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity